AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
PHARMACOKINETICS AND BIOAVAILABILITY OF ORAL 9-AMINOCAMPTOTHECIN CAPSULES IN ADULT PATIENTS WITH SOLID TUMORS
Authors: SPARREBOOM A DEJONGE MJA PUNT CJA NOOTER K LOOS WJ PORRO MG VERWEIJ J
Citation: A. Sparreboom et al., PHARMACOKINETICS AND BIOAVAILABILITY OF ORAL 9-AMINOCAMPTOTHECIN CAPSULES IN ADULT PATIENTS WITH SOLID TUMORS, Clinical cancer research, 4(8), 1998, pp. 1915-1919
THE USE OF INTERFERON-ALPHA IN THE TREATMENT OF CUTANEOUS MELANOMA - A REVIEW
Authors: PUNT CJA
Citation: Cja. Punt, THE USE OF INTERFERON-ALPHA IN THE TREATMENT OF CUTANEOUS MELANOMA - A REVIEW, Melanoma research, 8(2), 1998, pp. 95-104
5-FLUOROURACIL IN COLORECTAL-CANCER - RATIONALE AND CLINICAL-RESULTS OF FREQUENTLY USED SCHEDULES
Authors: KAMM YJL WAGENER DJT RIETJENS IMCM PUNT CJA
Citation: Yjl. Kamm et al., 5-FLUOROURACIL IN COLORECTAL-CANCER - RATIONALE AND CLINICAL-RESULTS OF FREQUENTLY USED SCHEDULES, Anti-cancer drugs, 9(5), 1998, pp. 371-380
IN-VITRO AND IN-VIVO BONE-MARROW TOXICITY ASSAYS IN THE CLINICAL DEVELOPMENT OF NEW DRUGS - CARZELESIN AS AN EXAMPLE
Authors: VANTELLINGEN O SCHAAF LJ PUNT CJA AWADA A VANDERVALK M HENRAR REC WAGENER DJT PICCART MJ NOOIJEN WJ BEIJNEN JH
Citation: O. Vantellingen et al., IN-VITRO AND IN-VIVO BONE-MARROW TOXICITY ASSAYS IN THE CLINICAL DEVELOPMENT OF NEW DRUGS - CARZELESIN AS AN EXAMPLE, Annals of oncology, 9, 1998, pp. 204-204
LIMITED-SAMPLING MODELS FOR 9-AMINOCAMPTOTHECIN PHARMACOKINETICS AFTER ORAL-DRUG ADMINISTRATION
Authors: SPARREBOOM A DEJONGE MJA PUNT CJA LOOS WJ DALLAIRE BK VERWEIJ J
Citation: A. Sparreboom et al., LIMITED-SAMPLING MODELS FOR 9-AMINOCAMPTOTHECIN PHARMACOKINETICS AFTER ORAL-DRUG ADMINISTRATION, Annals of oncology, 9, 1998, pp. 228-228
CLINICAL PHARMACOKINETICS OF ORAL 9-AMINOCAMPTOTHECIN IN PLASMA AND SALIVA - RELATIONSHIPS WITH HEMATOLOGIC TOXICITY
Authors: SPARREBOOM A DEJONGE MJA PUNT CJA LOOS WJ DALLAIRE BK VERWEIJ J
Citation: A. Sparreboom et al., CLINICAL PHARMACOKINETICS OF ORAL 9-AMINOCAMPTOTHECIN IN PLASMA AND SALIVA - RELATIONSHIPS WITH HEMATOLOGIC TOXICITY, Annals of oncology, 9, 1998, pp. 229-229
PHASE-I AND PHARMACOLOGICAL STUDY ON ORAL [PEG-1000] 9-AMINO-CAMPTOTHECIN (9-AC) IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: DEJONGE MJA PUNT CJA SPARREBOOM A LOOS WJ VANBEURDEN V PLANTING AST DALLAIRE B VERWEIJ J
Citation: Mja. Dejonge et al., PHASE-I AND PHARMACOLOGICAL STUDY ON ORAL [PEG-1000] 9-AMINO-CAMPTOTHECIN (9-AC) IN PATIENTS WITH ADVANCED SOLID TUMORS, Annals of oncology, 9, 1998, pp. 243-243
RESULTS OF INTERLEUKIN-2-BASED TREATMENT IN ADVANCED MELANOMA - A CASE RECORD-BASED ANALYSIS OF 631 PATIENTS
Authors: KEILHOLZ U CONRADT C LEGHA SS KHAYAT D SCHEIBENBOGEN C THATCHER N GOEY SH GORE M DORVAL T HANCOCK B PUNT CJA DUMMER R AVRIL MF BROCKER EB BENHAMMOUDA A EGGERMONT AMM PRITSCH M
Citation: U. Keilholz et al., RESULTS OF INTERLEUKIN-2-BASED TREATMENT IN ADVANCED MELANOMA - A CASE RECORD-BASED ANALYSIS OF 631 PATIENTS, Journal of clinical oncology, 16(9), 1998, pp. 2921-2929
A CLINICAL PHARMACOKINETICS STUDY OF CARZELESIN GIVEN BY SHORT-TERM INTRAVENOUS-INFUSION IN A PHASE-I STUDY
Authors: VANTELLINGEN O PUNT CJA AWADA A WAGENER DJT PICCART MJ GROOT Y SCHAAF LJ HENRAR REC NOOIJEN WJ BEIJNEN JH
Citation: O. Vantellingen et al., A CLINICAL PHARMACOKINETICS STUDY OF CARZELESIN GIVEN BY SHORT-TERM INTRAVENOUS-INFUSION IN A PHASE-I STUDY, Cancer chemotherapy and pharmacology, 41(5), 1998, pp. 377-384
RANDOMIZED TRIAL OF IRINOTECAN PLUS SUPPORTIVE CARE VERSUS SUPPORTIVECARE ALONE AFTER FLUOROURACIL FAILURE FOR PATIENTS WITH METASTATIC COLORECTAL-CANCER
Authors: CUNNINGHAM D PYRHONEN S JAMES RD PUNT CJA HICKISH TF HEIKKILA R JOHANNESEN TB STARKHAMMAR H TOPHAM CA AWAD L JACQUES C HERAIT P
Citation: D. Cunningham et al., RANDOMIZED TRIAL OF IRINOTECAN PLUS SUPPORTIVE CARE VERSUS SUPPORTIVECARE ALONE AFTER FLUOROURACIL FAILURE FOR PATIENTS WITH METASTATIC COLORECTAL-CANCER, Lancet, 352(9138), 1998, pp. 1413-1418
RESPONSE RATE AND PROGNOSTIC FACTORS OF RECURRENT OLIGODENDROGLIOMA TREATED WITH PROCARBAZINE, CCNU, AND VINCRISTINE CHEMOTHERAPY
Authors: VANDENBENT MJ KROS JM HEIMANS JJ PRONK LC VANGROENINGEN CJ KROUWER HGJ TAPHOORN MJB ZONNENBERG BA TIJSSEN CC TWIJNSTRA A PUNT CJA BOOGERD W
Citation: Mj. Vandenbent et al., RESPONSE RATE AND PROGNOSTIC FACTORS OF RECURRENT OLIGODENDROGLIOMA TREATED WITH PROCARBAZINE, CCNU, AND VINCRISTINE CHEMOTHERAPY, Neurology, 51(4), 1998, pp. 1140-1145
NEW DRUGS IN THE TREATMENT OF COLORECTAL-CARCINOMA
Authors: PUNT CJA
Citation: Cja. Punt, NEW DRUGS IN THE TREATMENT OF COLORECTAL-CARCINOMA, Cancer, 83(4), 1998, pp. 679-689
RECOMBINANT INTERLEUKIN-2-BASED TREATMENTS FOR ADVANCED MELANOMA - THE EXPERIENCE OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER MELANOMA COOPERATIVE GROUP
Authors: KEILHOLZ U STOTER G PUNT CJA SCHEIBENBOGEN C LEJEUNE F EGGERMONT AMM
Citation: U. Keilholz et al., RECOMBINANT INTERLEUKIN-2-BASED TREATMENTS FOR ADVANCED MELANOMA - THE EXPERIENCE OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER MELANOMA COOPERATIVE GROUP, The cancer journal from Scientific American, 3, 1997, pp. 22-28
PHARMACOKINETICS AND ORAL BIOAVAILABILITY OF 9-AMINO-CAMPTOTHECIN PEG1000 CAPSULES
Authors: SPARREBOORN A DEJONGE MJA LOOS WJ VANBEURDEN V PUNT CJA PLANTING AST VANDERBURG MEL COLAJORI E VERWEIJ J
Citation: A. Sparreboorn et al., PHARMACOKINETICS AND ORAL BIOAVAILABILITY OF 9-AMINO-CAMPTOTHECIN PEG1000 CAPSULES, European journal of cancer, 33, 1997, pp. 1112-1112
A RANDOMIZED TRIAL OF IFN-ALPHA IL-2 WITH OR WITHOUT CDDP IN ADVANCEDMELANOMA - AN EORTC MELANOMA COOPERATIVE GROUP TRIAL/
Authors: KEILHOLZ U GOEY SH PUNT CJA SCHEIBENBOGEN C PROEBSTLE T SALZMANN R SCHADENDORF D LIENARD D EGGERMONT AMM
Citation: U. Keilholz et al., A RANDOMIZED TRIAL OF IFN-ALPHA IL-2 WITH OR WITHOUT CDDP IN ADVANCEDMELANOMA - AN EORTC MELANOMA COOPERATIVE GROUP TRIAL/, European journal of cancer, 33, 1997, pp. 1159-1159
WEEKLY CHRONOMODULATED 48-H INFUSION OF HIGH-DOSE 5-FLUOROURACIL MODULATED BY METHOTREXATE AND (6S)-LEUCOVORIN IN ADVANCED COLORECTAL-CANCER - A PHASE-IB STUDY
Authors: PUNT CJA KAMM YL WAGENER DJT
Citation: Cja. Punt et al., WEEKLY CHRONOMODULATED 48-H INFUSION OF HIGH-DOSE 5-FLUOROURACIL MODULATED BY METHOTREXATE AND (6S)-LEUCOVORIN IN ADVANCED COLORECTAL-CANCER - A PHASE-IB STUDY, Anti-cancer drugs, 8(5), 1997, pp. 454-458
INTERFERON ALFA-2A AND INTERLEUKIN-2 WITH OR WITHOUT CISPLATIN IN METASTATIC MELANOMA - A RANDOMIZED TRIAL OF THE -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER MELANOMA COOPERATIVE GROUP
Authors: KEILHOLZ U GOEY SH PUNT CJA PROEBSTLE TM SALZMANN R SCHEIBENBOGEN C SCHADENDORF D LIENARD D ENK A DUMMER R HANTICH B GEUEKE AM EGGERMONT AMM
Citation: U. Keilholz et al., INTERFERON ALFA-2A AND INTERLEUKIN-2 WITH OR WITHOUT CISPLATIN IN METASTATIC MELANOMA - A RANDOMIZED TRIAL OF THE -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER MELANOMA COOPERATIVE GROUP, Journal of clinical oncology, 15(7), 1997, pp. 2579-2588
ADVANCED COLORECTAL-CANCER, REFRACTORY TO INFUSIONAL FLUOROURACIL TREATMENT - EFFICACY OF 2ND LINE FLUOROURACIL IN COMBINATION WITH A DIFFERENT BIOCHEMICAL MODULATION
Authors: VANHALTEREN HK WAGENER DJT VREUGDENHIL G PUNT CJA
Citation: Hk. Vanhalteren et al., ADVANCED COLORECTAL-CANCER, REFRACTORY TO INFUSIONAL FLUOROURACIL TREATMENT - EFFICACY OF 2ND LINE FLUOROURACIL IN COMBINATION WITH A DIFFERENT BIOCHEMICAL MODULATION, Anticancer research, 17(4A), 1997, pp. 2715-2719
CHEMOIMMUNOTHERAPY WITH BLEOMYCIN, VINCRISTINE, LOMUSTINE, DACARBAZINE (BOLD) PLUS INTERFERON-ALPHA FOR METASTATIC MELANOMA - A MULTICENTERPHASE-II STUDY
Authors: PUNT CJA VANHERPEN CML JANSEN RLH VREUGDENHIL G MULLER EW DEMULDER PHM
Citation: Cja. Punt et al., CHEMOIMMUNOTHERAPY WITH BLEOMYCIN, VINCRISTINE, LOMUSTINE, DACARBAZINE (BOLD) PLUS INTERFERON-ALPHA FOR METASTATIC MELANOMA - A MULTICENTERPHASE-II STUDY, British Journal of Cancer, 76(2), 1997, pp. 266-269
PHASE IB STUDY OF DOXORUBICIN IN COMBINATION WITH THE MULTIDRUG-RESISTANCE REVERSING AGENT S9788 IN ADVANCED COLORECTAL AND RENAL-CELL CANCER
Authors: PUNT CJA VOEST EE TUENI E VANOOSTEROM AT BACKX A DEMULDER PHM HECQUET B LUCAS C GERARD B BLEIBERG H
Citation: Cja. Punt et al., PHASE IB STUDY OF DOXORUBICIN IN COMBINATION WITH THE MULTIDRUG-RESISTANCE REVERSING AGENT S9788 IN ADVANCED COLORECTAL AND RENAL-CELL CANCER, British Journal of Cancer, 76(10), 1997, pp. 1376-1381
DOSE EFFICACY STUDY OF 2 SCHEDULES OF HIGH-DOSE BOLUS ADMINISTRATION OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN METASTATIC MELANOMA
Authors: KRUIT WHJ PUNT CJA GOEY SH DEMULDER PHM GRATAMA JW EGGERMONT AMM BOLHUIS RLH STOTER G
Citation: Whj. Kruit et al., DOSE EFFICACY STUDY OF 2 SCHEDULES OF HIGH-DOSE BOLUS ADMINISTRATION OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN METASTATIC MELANOMA, British Journal of Cancer, 74(6), 1996, pp. 951-955
TALLIMUSTINE IN ADVANCED PREVIOUSLY UNTREATED COLORECTAL-CANCER, A PHASE-II STUDY
Authors: PUNT CJA HUMBLET Y ROCA E DIRIX LY WAINSTEIN R POLLI A CORRADINO I
Citation: Cja. Punt et al., TALLIMUSTINE IN ADVANCED PREVIOUSLY UNTREATED COLORECTAL-CANCER, A PHASE-II STUDY, British Journal of Cancer, 73(6), 1996, pp. 803-804
FOTEMUSTINE IN PATIENTS WITH RELAPSING MALIGNANT GLIOMAS - A PHASE-IITRIAL
Authors: PUNT CJA STAMATAKIS L GERARD B
Citation: Cja. Punt et al., FOTEMUSTINE IN PATIENTS WITH RELAPSING MALIGNANT GLIOMAS - A PHASE-IITRIAL, Oncology Reports, 2(2), 1995, pp. 307-308
BONE-MARROW PROTECTION BY AMIFOSTINE (AMI) IN PATIENTS TREATED WITH CARBOPLATIN (CARBO) - A PHASE-I STUDY
Authors: VERMORKEN JB PUNT CJA EELTINK CM VANMAANEN L OSTER W VANHOUTEN MD VANDERVIJGH WJF
Citation: Jb. Vermorken et al., BONE-MARROW PROTECTION BY AMIFOSTINE (AMI) IN PATIENTS TREATED WITH CARBOPLATIN (CARBO) - A PHASE-I STUDY, European journal of cancer, 31A, 1995, pp. 962-962
FOTEMUSTINE AND TAMOXIFEN COMBINATION THERAPY IN METASTATIC MALIGNANT-MELANOMA - A PHASE-II STUDY
Authors: PUNT CJA TYTGAT JH VANLIESSUM PA GERARD B
Citation: Cja. Punt et al., FOTEMUSTINE AND TAMOXIFEN COMBINATION THERAPY IN METASTATIC MALIGNANT-MELANOMA - A PHASE-II STUDY, European journal of cancer, 31A(3), 1995, pp. 421-422
Risultati: 1-25 | 26-33